A comprehensive decade-long study has found no evidence linking routine childhood vaccinations—or the aluminum adjuvants they contain—to increased epilepsy risk.
Researchers from Marshfield Clinic Research Institute analyzed data from the CDC's Vaccine Safety Datalink, matching 2,089 children diagnosed with epilepsy between ages 1 and 4 with 20,139 children without epilepsy. The study controlled for age, sex, and healthcare facility.
The results were clear: neither vaccine schedules nor cumulative aluminum exposure increased epilepsy risk. As the authors stated, "The adjusted odds ratios for both measures did not exceed 1.0."
This matters right now. Federal agencies are reducing vaccine recommendations, and parental concerns about vaccine safety continue despite overwhelming evidence of their benefit. Studies like this provide the data parents need to make informed decisions.
One caveat: a subgroup analysis suggested very young infants (1-2 months) receiving aluminum hydroxide/phosphate combination vaccines showed roughly twice the odds of epilepsy diagnosis. However, this finding didn't reach statistical significance, and the researchers noted it requires further investigation.
The known risk factors told a clearer story. Children with prematurity, family epilepsy history, or pre-existing neurologic conditions showed substantially elevated epilepsy odds—regardless of vaccination status.
The study examined the most commonly administered childhood vaccines during a critical developmental window. Most participants were boys (54%), predominantly ages 1-23 months (69%), with demographic diversity across the cohort.
Science works by accumulation. No single study is definitive, but this adds to a mountain of evidence supporting childhood immunization safety. The diseases these vaccines prevent—measles, pertussis, polio—carry real risks of neurological damage and death.
The universe doesn't care what we believe. Let's find out what's actually true. In this case, the evidence continues to support vaccination.
